Development of Sarcoidosis Following Completion of Treatment for Hepatitis C with Pegylated Interferon-alpha 2a and Ribavirin: A Case Report and Literature Review

被引：17

作者：

Gayet, Alberic-Rembrandt ^{[1
]}

Plaisance, Patrick ^{[1
]}

Bergmann, Jean-Francois ^{[2
]}

Mouly, Stephane ^{[2
]}

机构：

[1] Lariboisiere Hosp, AP HP, Emergency Dept, Paris, France

[2] Lariboisiere Hosp, AP HP, Dept Internal Med, Paris, France

来源：

CLINICAL MEDICINE & RESEARCH | 2010年 / 8卷 / 3-4期

关键词：

Chronic hepatitis C; Interferon-alpha and ribavirin combination therapy; Sarcoidosis; Spontaneous recovery;

D O I：

10.3121/cmr.2010.886

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Sarcoidosis is a chronic inflammatory multisystem disease of unknown etiology. We report on a woman, aged 57 years, presenting with typical sarcoidosis occurring two months after completion of a six-month course of interferon-a and ribavirin for chronic hepatitis C virus infection. The current observation is interesting with regard to the time elapsed between the occurrence of symptoms and antiviral treatment withdrawal, and spontaneous recovery after ten months of follow-up. Pathophysiological mechanisms involved in the development of antiviral therapyinduced sarcoidosis are discussed.

引用

页码：163 / 167

页数：5

共 50 条

[41] Subcutaneous Sarcoidosis during Pegylated Interferon Alfa and Ribavirin Treatment for Chronic Hepatitis C
Rodriguez-Lojo, R.
Almagro, M.
Barja, J. M.
Pineyro, F.
Perez-Varela, L.
Del Pozo, J.
Yebra-Pimentel, M. T.
Fonseca, E.
DERMATOLOGY RESEARCH AND PRACTICE, 2010, 2010
[42] Interferon-alpha 2a Ribavirin versus Interferon- alpha 2a alone for the retreatment of hepatitis C patients who relapse after a standard course of Interferon
Chapman, BA
Stace, NH
Edgar, CL
Bartlett, SE
Frampton, CMA
Scahill, SL
Jennings, LC
NEW ZEALAND MEDICAL JOURNAL, 2001, 114 (1128) : 103 - 104
[43] Thyroid disturbances in children treated with combined pegylated interferon-alpha and ribavirin for chronic hepatitis C
Rashed, Yasser K.
Khalaf, Fatma A.
Kotb, Sobhy E.
CLINICAL AND EXPERIMENTAL PEDIATRICS, 2020, 63 (02) : 52 - 55
[44] Autoimmune Hepatitis Triggered by Treatment With Pegylated Interferon alpha-2a and Ribavirin for Chronic Hepatitis C
Rathi, Chetan
Pipaliya, Nirav
Choksi, Dhaval
Parikh, Pathik
Ingle, Meghraj
Sawant, Prabha
ACG CASE REPORTS JOURNAL, 2015, 2 (04): : 247 - 249
[45] Development of myasthenia gravis due to treatment of chronic hepatitis C with a combination of interferon-alpha and ribavirin
Bektas, M.
Bektas, H.
Goren, D.
Altan, M.
Cetinkaya, H.
DIGESTION, 2007, 75 (04) : 208 - 209
[46] Vitiligo associated with pegylated interferon and ribavirin treatment of patients with chronic hepatitis C: A case report
Tomasiewicz, K
Modrzewska, R
Semczuk, G
ADVANCES IN THERAPY, 2006, 23 (01) : 139 - 142
[47] Pegylated interferon α-2a and -2b in combination with ribavirin in the treatment of chronic hepatitis C:: a systematic review and economic evaluation
Shepherd, J
Brodin, H
Cave, C
Waugh, N
Price, A
Gabbay, J
HEALTH TECHNOLOGY ASSESSMENT, 2004, 8 (39) : 1 - +
[48] Vitiligo associated with pegylated interferon and ribavirin treatment of patients with chronic hepatitis C: A case report
Krzysztof Tomasiewicz
Romana Modrzewska
Grażyna Semczuk
Advances in Therapy, 2006, 23
[49] Pilot study of pegylated interferon-alpha 2a in dialysis patients with chronic hepatitis C virus infection
Chan, Tak Mao
Ho, Stephen K. N.
Tang, Colin S. O.
Tse, Kai Chung
Lam, Man Fai
Lai, Kar Neng
Yung, Susan
NEPHROLOGY, 2007, 12 (01) : 11 - 17
[50] Exacerbation of Sarcoidosis Following Interferon-alpha Therapy for Chronic Active Hepatitis C
Chang, Hye Jung
Choi, Eun Hwa
Kim, In Je
Sim, Yun Su
Lee, Jin Hwa
Kim, Tae Hun
Moon, Jin Wook
Chun, Eun Mi
Kim, Yoo Kyung
Sung, Sun Hee
Chang, Jung Hyun
TUBERCULOSIS AND RESPIRATORY DISEASES, 2006, 61 (03) : 285 - 288

← 1 2 3 4 5 →